SEC Tracker
Get the app

AbbVie ABBV

AbbVie reports director resignation

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Jennifer L. Davis resigns from AbbVie's Board effective November 2, 2026
  2. Davis appointed CEO at Align Technology, Inc.
  3. Resignation not due to disputes with AbbVie

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when AbbVie files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 6 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, AbbVie Inc. reported: Revenue $17.0 billion.
  • Net income $3.6 billion.
  • Gross margin 74.7%.
  • Operating margin 37.9%.
  • Net margin 21.3%.
  • Revenue change from a year earlier +10.2%.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Johnson & Johnson JNJ public float $367.0B, Jun 29, 2025
  2. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  3. Merck MRK public float $198.1B, Jun 30, 2025
  4. Pfizer PFE public float $138.0B, Jun 29, 2025
  5. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025